Introduction {#s1}
============

Leprosy, a chronic infectious disease caused by the obligate intracellular bacterium *Mycobacterium leprae*, remains a major source of morbidity in developing countries [@pntd.0002381-WHO1]. The disease affects mainly the skin and the peripheral nervous system, in which the leprosy bacillus is preferentially found inside macrophages and Schwann cells (reviewed in [@pntd.0002381-Scollard1]). Multidrug therapy (MDT), a combination of antibiotics that are very effective in eliminating *M. leprae*, was introduced by WHO in the early eighties. However, despite efforts to treat registered leprosy patients, the number of new cases reported globally remains stable and high (about 200,000/year). The disease is still considered a public health problem in several countries. In Brazil, the detection rate remains high and stable at approximately 40,000 new cases annually [@pntd.0002381-WHO1]. Moreover, nerve damage may progress during MDT itself and even subsequent to patient release, due mainly to the occurrence of acute immune-inflammatory episodes known as leprosy reactions. Therefore, new strategies and approaches need to be developed in order to decrease disease morbidity and fully eradicate leprosy as a public health problem.

Also known as Hansen\'s disease, leprosy manifests as a spectrum of clinical forms in correlation with the nature and magnitude of the innate and adaptive immune responses generated during infection. At one extreme of the spectrum, individuals with polar tuberculoid (TT) leprosy have few lesions and manifest a contained, self-limited infection in which scarce bacilli are detected due to the generation of a strong cellular immune response against *M. leprae*. At the other end, lepromatous leprosy (LL) is a progressively disseminating disease characterized by extensive bacterial multiplication within host cells and low cell-mediated immunity to the pathogen. Between these two poles are the borderline forms (characterized by their intermediate clinical and immunological patterns), commonly referred to as borderline tuberculoid (BT), borderline borderline (BB), and borderline lepromatous (BL) in accordance with their proximity to either one of the spectral extremes (reviewed in [@pntd.0002381-Scollard1]).

Leprosy is a complex disease, and is essentially restricted to human beings. Despite considerable research efforts over the last decades, our understanding of the mechanisms that govern leprosy pathogenesis remains limited. The unique features of the leprosy bacillus have contributed to the slow progress in our knowledge of leprosy. One peculiar characteristic of *M. leprae* is its extremely long generation time, estimated to be nearly 2 weeks. This slow growth rate results in long incubation periods (2--10 years) and very slow development of pathology and clinical evolution (reviewed in [@pntd.0002381-Scollard1]). In the absence of an animal experimental model that mimics the disease in humans, progress in our knowledge of leprosy pathogenesis relies on observations obtained from infected populations and on analyses of clinical samples collected directly from leprosy patients. However, continuing improvements in analytical technologies and recent developments of sensitive high-throughput techniques are now opening a new opportunity to study this ancient disease in order to suggest new strategies for leprosy prevention and treatment. Of note, techniques that identify and quantify multiple small metabolites (\<1,500 Da) in complex biological samples have been recently developed, giving rise to the field of metabolomics (or metabonomics). Metabonomics has been successfully applied to different biofluids and tissue types, revealing their biochemical composition in different pathological conditions [@pntd.0002381-Antunes1], [@pntd.0002381-Denery1], [@pntd.0002381-Lakshmanan1].

The complex interplay between pathogens and their hosts has profound effects on host metabolism during infection. Since the tuberculoid and lepromatous forms of leprosy constitute different responses of the host to *M. leprae* infection, we hypothesized that host metabolism in response to infection would be distinct in these different clinical forms of the disease. Even though *M. leprae* is an obligate intracellular parasite, patient plasma/serum offers an important window for detecting metabolic modulation since blood contains many molecules that are released by different tissues in response to infection. A recent metabolomic study of human serum has identified and quantified more than 4,000 metabolites generating the Human Serum Database [@pntd.0002381-Psychogios1].

To explore the perturbations in the human metabolome associated with *M. leprae* infection, we analyzed the repertoire of metabolites present in serum samples of leprosy patients. We used direct-infusion ultrahigh resolution Fourier transform ion cyclotron resonance mass spectrometry (DI-FT-ICR-MS), a powerful technique that allows the presumptive identification and relative quantification of thousands of metabolites with high mass accuracy and without the need for extensive sample preparation [@pntd.0002381-Han1]. Our results indicate a marked modulation of omega-6 and omega-3 polyunsaturated fatty acids (PUFA) metabolism during *M. leprae* infection, which disappears after MDT. Effects of *M. leprae* infection on PUFA metabolism were confirmed by measurements through enzyme-linked immunoassays using serum, which showed significantly higher levels of prostaglandin (PG) D~2~ and E~2~ (PGD~2~ and PGE~2~), lipoxin A~4~ (LXA~4~) and resolving D~2~ (RvD~2~) in untreated leprosy patients. Moreover, high-throughput metabolic profiling of skin specimens revealed an abundance of lipase products in LL patients, such as polyunsaturated fatty acids and lysolecithin, corroborating the serum metabolome data. This study demonstrates the power of metabonomics to unravel metabolic modulation during infection and provides the opportunity to identify novel therapeutic targets and biomarkers for leprosy.

Materials and Methods {#s2}
=====================

Ethics statement {#s2a}
----------------

The Ethics Committee of the Oswaldo Cruz Foundation approved all procedures described in this study. All subjects, none of which were minors, provided informed written consent.

Patients and specimens {#s2b}
----------------------

Leprosy patients (29 LL and 29 BT) were recruited on a volunteer basis from the Leprosy Outpatient Unit (Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil). Patients were classified with leprosy according to the criteria of Ridley and Jopling [@pntd.0002381-Ridley1], and serum samples were taken before and right after MDT conclusion (without fasting). Skin biopsy specimens (6-mm punch) were also collected from LL and BT patients before treatment and were used for metabolite extraction. The baseline characteristics of each group of individuals included in the study are shown in [Table 1](#pntd-0002381-t001){ref-type="table"}. None of the patients were under anti-inflammatory therapy at the time of serum and biopsy specimen collection.

10.1371/journal.pntd.0002381.t001

###### Baseline characteristics of leprosy patients and healthy controls.

![](pntd.0002381.t001){#pntd-0002381-t001-1}

  Clinical sample                                 Sera    Skin biopsies                                                                                              
  --------------------------------------------- -------- --------------- ------------------------------------ -------- ------------------------------------ -------- -----------------------------------
  Individuals (n)                                  10           4         25[c](#nt104){ref-type="table-fn"}     4      25[d](#nt105){ref-type="table-fn"}     4      4[e](#nt106){ref-type="table-fn"}
  Male                                             6            3                         9                      3                      18                     2                      2
  Female                                           4            1                         16                     1                      7                      2                      2
  Age (median)                                    34.2        50.5                        48                    61.5                    50                     44                    75
  Age (min-max)                                  18--52      32--56                     11--66                 50--87                 22--87                 31--63                56--88
  BI (median)[b](#nt103){ref-type="table-fn"}      \-           0                         0                     3.91                   4.33                    0                    4.25

Groups included in this study: controls; BT, borderline tuberculoid patients; LL, lepromatous patients.

EIA, enzyme-linked immunoassay; FTICRMS, Fourier transform ion cyclotron resonance mass spectrometry.

BI, baciloscopic index.

Four of these patients underwent Type I reaction during treatment.

Nine patients developed Type II reaction and two developed Type I reaction.

One patient underwent Type II reaction.

Metabolite extraction {#s2c}
---------------------

Serum samples were thawed and 200 µL of serum were extracted overnight at −20°C in 2-mL tubes with 750 µL of methanol/chloroform (2∶1, v/v) followed by vortexing and centrifugation at 1,500×*g* for 5 minutes at 4°C. It is important to note that serum samples were never thawed before the metabonomics analysis described below was performed. The supernatants were carefully transferred to new tubes and the samples were extracted once again with 500 µL of methanol/chloroform/water (2∶1∶0.8, v/v/v), vortexed, and centrifuged as described before [@pntd.0002381-Han1]. The extracts were pooled, concentrated in a speedvac evaporator and dried under a nitrogen stream. For metabolite extraction of frozen biopsies, specimens were thawed on ice, mechanically disrupted, and extracted with chloroform/methanol/water (1∶2∶0.8, v/v/v) [@pntd.0002381-Bligh1]. Samples were then partitioned with chloroform and methanol (2∶1, v/v), according to the standard procedure of Folch *et al.* (1957) [@pntd.0002381-Folch1]. Pellets were extracted again with acetonitrile (10 µL of acetonitrile for each mg of initial tissue) by vortexing for 10 minutes. Samples were clarified by centrifugation at 16,000×*g* for 5 minutes, all phases were combined and extracts were dried and saved for further analysis.

Direct Infusion Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (DI-FT-ICR-MS) {#s2d}
------------------------------------------------------------------------------------------

For metabolic profiling of sera, dried extracts were suspended in 70% methanol (100 µL for each µL of sample), vortexed, and cleared by centrifugation. Supernatants were collected and used as described below. Extracts were diluted 1∶3 with 70% methanol containing either 0.2% formic acid (for positive ionization mode) or 0.2% ammonium hydroxide (for negative ionization mode) and spiked with predefined amounts of an ES tuning mix solution as the internal standard for mass calibration. For metabolic profiling of skin biopsies, dried extracts were resuspended in 60% acetonitrile (100 µL per 10 mg of sample), vortexed, sonicated and cleared by centrifugation. Extracts were diluted 1∶3 in ESI standard solutions containing either 0.2% formic acid (positive ion mode) or 0.5% ammonium hydroxide (negative ion mode). Solutions were then infused, using a syringe pump (KDS Scientific, Holliston, MA), at a flow rate of 2.5 µL per minute, into a 12-T Apex-Qe hybrid quadrupole-FT-ICR mass spectrometer (Bruker Daltonics, Billerica, MA) equipped with an Apollo II electrospray ionization source, a quadrupole mass filter, and a hexapole collision cell. Data were recorded in positive and negative ion modes with broadband detection and an FT acquisition size of 1,024 kilobytes per second within an *m/z* range of 150 to 1,100. Other experimental parameters were: capillary electrospray voltage of 3,600 to 3,750 V, spray shield voltage of 3,300 to 3,450 V, source ion accumulation time of 0.1 second, and collision cell ion accumulation time of 0.2 second. To increase detection sensitivity, survey scan mass spectra in positive- and negative-ion modes were acquired from the accumulation of 200 (sera) or 400 (skin) scans per spectrum.

DI-FT-ICR-MS data processing {#s2e}
----------------------------

Raw mass spectrometry data were processed using a custom-developed software package, as described elsewhere [@pntd.0002381-Han1]. Then, data analysis proceeded as previously described [@pntd.0002381-Antunes1], [@pntd.0002381-Antunes2]. Principal Component Analysis (PCA) was performed using the freely available software Multibase (<http://www.numericaldynamics.com/>). To identify differences in metabolite composition between BT and LL sera and skin samples, and sera from both groups before and after MDT, we manually selected two groups of metabolites. The first group comprised metabolites that were present in one set of samples but not the other. The second group comprised metabolites present in the two sets of samples being compared, but at different levels. To identify the metabolites in the second group, we averaged the mass intensities of metabolites in each set of samples (BT or LL, before or after MDT) and calculated the ratios between averaged intensities of metabolites from those samples. To assign possible metabolite identities to *m/z* values present in one group of samples but not the others as well as those *m/z* showing at least a 2-fold change in intensity between sets of samples, *m/z* of interest were queried against MassTRIX (version 2, <http://metabolomics.helmholtz-muenchen.de/masstrix2/>), a free-access software designed to incorporate masses into metabolic pathways using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (<http://www.genome.jp/kegg/>).

Lipoxin A~4~, prostaglandin D~2~, prostaglandin E~2~, leukotriene B~4~ and resolvin D1 measurements {#s2f}
---------------------------------------------------------------------------------------------------

Lipoxin A~4~ (LXA~4~), prostaglandin D~2~ (PGD~2~), prostaglandin E~2~ (PGE~2~), leukotriene B~4~ (LTB~4~) and resolvin D1 (RvD1) levels were measured in serum samples taken from BT (n = 20) and LL (n = 19) patients prior to and after MDT. In addition, measurements of these eicosanoids in serum samples from 10 healthy controls were taken for comparison. We used serum samples that had never been thawed and had been stored at −20°C. Measurements were performed using commercially-available kits according to the manufacturer\'s instructions. PGD~2~, PGE~2~, LTB~4~ and RvD1 enzyme-linked immunoassay (EIA) kits were purchased from Cayman Chemical (Ann Arbor, USA). The LXA~4~ EIA kit was from Neogen (Lexington, USA). LXA~4~ and RvD1 were extracted from serum samples using C~18~ Sep-Pak columns (Waters; Elstree, UK) before analysis, following the manufacturer\'s protocol.

Statistical analysis {#s2g}
--------------------

Data were analyzed by two-tailed unpaired or paired *t* tests with 95% confidence intervals or Kruskall--Wallis non-parametric analysis of variance (ANOVA) and Dunn\'s multiple-range post hoc test, as indicated. Outliers were detected using the Grubbs\' test and removed from data sets when indicated.

Results {#s3}
=======

BT and LL leprosy patients exhibit distinct serum metabolite profiles {#s3a}
---------------------------------------------------------------------

Serum samples were obtained from 4 BT and 4 LL patients to analyze metabolic alterations during the course of leprosy, and DI-FT-ICR-MS was used to detect and relatively quantify small metabolites in these samples. Such high-throughput analysis yielded a total of 2,565 different *m/z* (metabolite features) from both BT and LL groups, which were detected from combined positive and negative ion modes ([Table S1](#pntd.0002381.s006){ref-type="supplementary-material"}). A Principal Component Analysis plot ([Figure 1A](#pntd-0002381-g001){ref-type="fig"}) illustrates the extensive differences in metabolic composition between sera from BT and LL patients. Due to the sample size no analysis could be done on gender and age. Nevertheless, a more refined analysis was then carried out to determine the extent of the metabolic differences between BT and LL leprosy patients. To investigate which of the metabolites detected in both BT and LL samples were present at different levels in these groups, the average intensities of all metabolites were calculated and results from each of the sample groups (BT and LL) were compared. Metabolites that showed changes of 2-fold or more were used for further analyses. Based on this analysis criterion, we found that 684 of the total 2,565 metabolites were present at different levels when comparing samples from BT and LL patients ([Table S1](#pntd.0002381.s006){ref-type="supplementary-material"}). This represents 26.7% of all detected *m/z*, supporting the notion that an extensive metabolic shift occurs during disease. Metabolite levels were affected to various degrees, with changes ranging from 2-fold to over 30-fold. The complete serum DI-FT-ICR-MS raw data set is shown in [Tables S2](#pntd.0002381.s007){ref-type="supplementary-material"} and [S3](#pntd.0002381.s008){ref-type="supplementary-material"}.

![Metabonomics analysis of sera from leprosy patients.\
(a) Principal component analysis of metabolic alterations on sera from borderline tuberculoid (BT) and polar lepromatous leprosy (LL) patients. Raw DI-FT-ICR-MS data in both negative and positive ionization modes were combined and PCA was performed using Multibase (<http://www.numericaldynamics.com/>). Sample groups are indicated by the dashed lines. (b) Metabolic pathways altered in the polar forms of leprosy. *m/z* of interest detected in both negative and positive ionization modes were searched against the KEGG database (<http://www.genome.jp/kegg/>) using the MassTRIX software (version 2, <http://metabolomics.helmholtz-muenchen.de/masstrix2/>). Bars indicate the number of metabolic features from each KEGG pathway that was affected by infection. Gray bars represent the number of metabolic features that were found in higher levels in BT patients (\>2 fold), whereas white bars represent the metabolic features found in higher levels in LL patients.](pntd.0002381.g001){#pntd-0002381-g001}

Polyunsaturated fatty acid metabolites are increased in sera from LL patients when compared to BT patients {#s3b}
----------------------------------------------------------------------------------------------------------

In order to identify the metabolic pathways most significantly disturbed during leprosy, we selected metabolites detected in both BT and LL patients showing at least a 2-fold difference between them and queried the MassTRIX database (version 2, <http://metabolomics.helmholtz-muenchen.de/masstrix2/>) to determine putative metabolite identities. [Figure 1B](#pntd-0002381-g001){ref-type="fig"} shows the categories of metabolites that differ between the two groups. Although many metabolic pathways were affected, our data suggest that the metabolism of omega-6 (linoleic and arachidonic acids) and omega-3 PUFAs (α-linolenic acid, EPA and DHA) are markedly modulated during *M. leprae* infection, with higher levels of a diverse class of bioactive lipid mediators in LL sera when compared to BT sera. The effects of *M. leprae* infection on specific classes of PUFAs are described in more detail below.

### Arachidonic acid metabolism {#s3b1}

The arachidonic acid (AA) pathway was the metabolic route with the highest number of metabolites having increased levels in sera of LL patients (58 potential metabolites) when compared to BT patients. On the other hand, only one putative metabolite in this pathway showed increased levels in BT patients when compared to LL patients. [Figure S1](#pntd.0002381.s001){ref-type="supplementary-material"} shows the human metabolic pathway of AA as it appears in KEGG, indicating the potential metabolites affected in LL serum. Besides AA itself (*m/z* 303.23292), several *m/z* corresponding to an array of potential AA derivatives were detected in higher levels (two fold or higher) in LL sera. These *m/z*, together with their corresponding potential identities and relative levels detected in LL versus BT patients are shown in [Table 2](#pntd-0002381-t002){ref-type="table"}. Although statistical analysis did not yield significant *p*-values (*p*\>0.05), this is not surprising due to the limited number of samples used and the inherent variability amongst human samples. Nevertheless, the high number of metabolites in this pathway that were identified by our exploratory method suggests that this is indeed an important component of the host\'s response to *M. leprae* infection.

10.1371/journal.pntd.0002381.t002

###### Comparison of the relative levels[a](#nt107){ref-type="table-fn"} of metabolites of the arachidonic acid pathway in sera from BT and LL patients before and after antibiotic treatment.

![](pntd.0002381.t002){#pntd-0002381-t002-2}

  *m/z*               Compound              BT          LL                     
  ----------- ------------------------- ---------- ------------- ------------- -------------
  303.23292       arachidonic acid       100%(38)    56.0%(18)    261.6%(190)    55.8%(12)
  317.21222           5-oxo-ETE          100%(45)    33.4%(14)    292.8%(199)    25.8%(7)
                     12-oxo-ETE                                                
                     15-oxo-ETE                                                
                       LTA~4~                                                  
  319.22782             EETs             100%(41)    34.0%(24)    654.4%(537)    23.0%(8)
                        HETEs                                                  
                       5-HETE                                                  
                     15(R)-HETE                                                
                     15(S)-HETE                                                
                     19(S)-HETE                                                
                       20-HETE                                                 
  325.20202    2,3-dinor-8-iso-PGF~2α~   100%(19)   102.7%(44)    352.1%(246)   120.0%(55)
  327.21782    2,3-dinor-8-iso-PGF~1α~   100%(21)   189.6%(100)   513.7%(314)   246.1%(134)
  333.20712            PGA~2~            100%(58)   112.4%(16)    699.0%(511)    80.8%(38)
                       PGB~2~                                                  
                       PGC~2~                                                  
                       PGJ~2~                                                  
                    Δ^12^-PGJ~2~                                               
                   12-keto-LTB~4~                                              
                 5,6-epoxy-tetraene                                            
  335.22282            HPETEs            100%(48)    26.9%(17)    367.6%(275)    21.0%(9)
                       5-HPETE                                                 
                     15(S)-HPETE                                               
                   hepoxilin A~3~                                              
                   hepoxilin B~3~                                              
                   11H-14,15-EETA                                              
                   15H-11,12-EETA                                              
                       LTB~4~                                                  
                    20-OH-LTB~4~                                               
  337.23842             DHETs            100%(27)    80.9%(30)    443.0%(342)    34.1%(10)
  351.21782            TXA~2~            100%(60)    25.1%(11)    245.9%(163)    22.4%(8)
                    prostacyclin                                               
                       PGD~2~                                                  
                       PGE~2~                                                  
                       PGH~2~                                                  
                   15-keto-PGF~2α~                                             
                       LXA~4~                                                  
                       LXB~4~                                                  
  369.22832            TXB~2~            100%(60)    33.7%(9)     405.1%(273)    44.7%(16)
                   6-keto-PGF~1α~                                              

Absent values were substituted with the limit of detection, represented by the lowest intensity value of any given sample. Then, averaged values from the untreated BT serum samples (n = 4) were normalized to 100% and other samples were normalized accordingly. SD are shown in parentheses. PG, prostaglandin; LT, leukotriene; TX, thromboxane; EET, epoxyeicosatrienoic acid; oxo-ETE, oxoicosatetraenoic acid; HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; DHET, dihydroxyeicosatrienoic acid.

Through the action of cyclooxygenases (COX), AA is transformed to PGG~2~ and then to PGH~2~, which may be metabolized to other PGs (PGD~2~, PGE~2~, PGI~2~ and PGF~2α~) and thromboxanes (TXA~2~ and TXB~2~). Several of these compounds, as well as their downstream products, were found in higher levels in LL sera, suggesting high activity of cyclooxygenases during *M. leprae* infection. PGF~2α~ is an important AA metabolite involved in chronic and acute inflammation. It has a local action and is quickly degraded to 15-keto-PGF~2α~ upon reaching the bloodstream. Levels of this metabolite are used as a parameter to measure the *in vivo* biosynthesis of PGF~2α~, as well as its release (reviewed in [@pntd.0002381-Basu1]). An increase in the relative levels of a compound of *m/z* \[M-H\]^−^ 351.21782, which may correspond to 15-keto-PGF~2α~ (among others), was observed in LL patients ([Table 2](#pntd-0002381-t002){ref-type="table"}). TXA~2~ and PGI~2~ are substances with opposite effects: while TXA~2~ is produced by platelets, has vasoconstrictive properties, and stimulates platelet aggregation, PGI~2~ is a vasodilator synthesized by macrovascular endothelial cells that inhibits platelet activation, modulating platelet-vascular interactions [@pntd.0002381-Cheng1]. TXA~2~ and PGI~2~ have the same molecular mass (*m/z* \[M-H\]^−^ 351.21782), and the same is true for their respective degradation products, TXB~2~/6-keto-PGF~1α~ (*m/z* \[M-H\]^−^ 369.22832) and 11-dehydro-TXB~2~/6-keto-PGE~1~ (*m/z* \[M-H\]^−^ 367.21282). All of these *m/z* were present in higher levels in LL sera ([Table 2](#pntd-0002381-t002){ref-type="table"}).

Another fate of AA is its metabolism by lipoxygenases (5-, 12- or 15-LOX), leading to the formation of LTs, LXs and hepoxilins (HX). Hydroperoxyeicosatetraenoic acids (5-, 12-, or 15-HPETEs), hydroxyeicosatetraenoic acids (5-, 12- or 15-HETEs) and oxo-ETEs are bioactive products of these pathways (reviewed in [@pntd.0002381-Buczynski1]). Several of these compounds and their degradation products such as DHETs were found in higher levels in LL sera, suggesting a high activity of LOXs during *M. leprae* infection ([Table 2](#pntd-0002381-t002){ref-type="table"}). Peroxidation of AA occurs in the presence of free radicals, leading to the non-enzymatic formation of 8-isoprostane (8-iso-PGF~2α~), which possesses vasoconstrictive activities and induces the COX-mediated formation of PGF~2α~. 8-isoprostane has a short half-life, being metabolized to 2,3-dinor-8-iso-PGF~2α~ and 2,3-dinor-5,6-dihydro-8-iso-PGF~2α~, among others (reviewed in [@pntd.0002381-Basu1]). In sera from LL patients, higher levels of 2,3-dinor-8-iso-PGF~2α~, but not of 8-isoprostane, were observed ([Table 2](#pntd-0002381-t002){ref-type="table"}), which could be linked to the higher oxidative stress and lower antioxidant capacity observed in leprosy, more specifically in patients with the lepromatous form [@pntd.0002381-Prasad1], [@pntd.0002381-Jyothi1].

### Linoleic acid metabolism {#s3b2}

Linoleic acid may be converted to AA or suffer epoxygenation, generating an array of different biologically active products [@pntd.0002381-Patwardhan1]. As shown in [Table 3](#pntd-0002381-t003){ref-type="table"} and [Figure S2](#pntd.0002381.s002){ref-type="supplementary-material"}, an *m/z* that may correspond to linoleic acid (*m/z* 279.23282) as well as other linoleic acid derivatives was found in higher levels in LL sera ([Table 3](#pntd-0002381-t003){ref-type="table"}). These include the 9,10- and 12,13-epoxyoctadecamonoenoic acids (9(10)-EpOME and 12(13)-EpOME, respectively; *m/z* 295.22782), also known as leukotoxins, and which are generated from activated neutrophils and macrophages and can induce cell death. The toxic effects of these metabolites are thought to be mediated by their conversion into the corresponding diols 9,10- and 12,13-diHOME by soluble epoxide hydrolase [@pntd.0002381-Moghaddam1]. On the other hand, one *m/z* that may correspond to a lecithin was found in higher levels in BT sera (*m/z* 704.52438, data not shown).

10.1371/journal.pntd.0002381.t003

###### Comparison of the relative levels[a](#nt108){ref-type="table-fn"} of metabolites of the linoleic acid pathway in sera from BT and LL patients before and after antibiotic treatment.

![](pntd.0002381.t003){#pntd-0002381-t003-3}

  *m/z*                        Compound                      BT          LL                         
  ----------- ------------------------------------------ ---------- ------------- ----------------- -------------
  277.21732                  γ-linolenate                 100%(27)    63.8%(23)      200.5%(107)     135.2%(29)
                             crepenynate                                                            
  279.23282                   linoleate                   100%(33)    61.2%(23)      310.8%(227)     110.9%(22)
                 9-*cis*,11-*trans*-octadecadienoate                                                
  293.21222                    9-oxoODE                   100%(35)    71.4%(33)    1,720.1%(1,582)   126.9%(63)
                              13-oxoODE                                                             
  295.22782                   9(S)-HODE                   100%(56)     3.7%(0)     1,962.6%(1,841)    77.7%(45)
                             12(13)-EpOME                                                           
                             9(10)-EpOME                                                            
                              13(S)-HODE                                                            
  329.23342                9,12,13-TriHOME                100%(19)   175.8%(112)    1,197.8%(997)    291.9%(229)
                           9,10,13-TriHOME                                                          
               9,10-dihydroxy-12,13-epoxy-octadecanoate                                             
  826.66842                    lecithin                   100%(22)   188.1%(37)      215.0%(48)      267.5%(22)

Absent values were substituted with the limit of detection, represented by the lowest intensity value of any given sample. Then, averaged values from the untreated BT serum samples (n = 4) were normalized to 100% and other samples were normalized accordingly. SD are shown in parentheses. EpOME, epoxyoctadecenoic acid; HODE, hydroxyoctadecadienoic acid; TriHOME, trihydroxyoctadecenoic acid; oxoODE, oxooctadecadienoic acid.

Linoleic acid can also be hydroxylated by both CYP and LOX to form HODEs, which can subsequently be oxidized to form oxoocta-decadienoic acids (oxoODEs). Compounds with *m/z* 293.21222 and *m/z* 295.22782, corresponding to potential oxoODEs and HODE, respectively, were detected in higher levels in sera from LL patients ([Table 3](#pntd-0002381-t003){ref-type="table"}). These metabolites have been shown to be potent activators of peroxisome proliferator-activated receptor gamma, PPAR-γ [@pntd.0002381-Altmann1]. As with metabolites in the arachidonic acid pathway, statistical analysis of the results obtained with metabolites of linoleic acid metabolism did not yield significant *p*-values (*p*\>0.05) due to the limited number of samples used and the inherent variability amongst human samples. Nevertheless, the overrepresentation of this pathway in our metabonomics analysis suggests that it is also an important player in the pathophysiology of leprosy.

### Omega-3 polyunsaturated fatty acid metabolism {#s3b3}

Finally, higher relative amounts of potential metabolites derived from the omega-3 polyunsaturated fatty acids were observed in sera from LL patients when compared to sera from BT patients, as seen in [Table 4](#pntd-0002381-t004){ref-type="table"}. Again, statistical analysis did not yield significant *p*-values (*p*\>0.05) due to the reasons mentioned previously but many metabolites of this pathway showed relative changes in the different patient groups, suggesting that this may be another important player during leprosy that should be investigated further. The α-linolenic acid metabolism in humans and the potential metabolites derived from omega-3 fatty acids with increased levels in LL in comparison to BT are indicated in [Figure S3](#pntd.0002381.s003){ref-type="supplementary-material"}. Recently, the metabolism of omega-3 fatty acids, more specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has received considerable attention due to their anti-inflammatory, pro-resolving activities. EPA and DHA can be obtained directly from the diet or from enzymatic conversions of linolenic acid. Metabolites with masses corresponding to EPA (*m/z* 301.21732) and DHA (*m/z* 327.23302) were found in BT and LL sera, with higher levels being found in sera of LL patients. Both EPA and DHA are metabolized to 3-series PGs and TXs, 5-series LTs, E- and D-series resolvins (RvE and RvD), aspirin D-series resolvins, (neuro)protectin D1 (PD1) and maresins (MaR), respectively, which exert anti-inflammatory and pro-resolution effects (reviewed in [@pntd.0002381-Serhan1]). Interestingly, particularly higher levels of *m/z* 333.20712 and 375.21792, which may correspond to RvE2 and RvD1-RvD4, respectively, were detected in sera from LL patients ([Table 4](#pntd-0002381-t004){ref-type="table"}). Of note, higher levels of *m/z* 359.22292, which may correspond to 6 different metabolites \[RvD5, RvD6, (N)PD1, MaR1, 17-HpDHA (a marker of the D-series Rvs and (N)PD1 biosynthetic pathway) and 14-HpDHA (an intermediate in the synthesis of MaR1)\] were also found in sera from LL patients. These data suggest that the metabolism of PUFAs is severely disturbed during leprosy; our data suggest that the production of anti-inflammatory, pro-resolving Rvs, PD1 and MaR derived from omega-3 fatty acid metabolism is highly exacerbated during leprosy, especially in its lepromatous form.

10.1371/journal.pntd.0002381.t004

###### Comparison of the relative levels[a](#nt109){ref-type="table-fn"} of omega-3 polyunsaturated fatty acids derivates in sera from BT and LL patients before and after antibiotic treatment.
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  *m/z*            Compound          BT          LL                    
  ----------- ------------------ ---------- ------------ ------------- ------------
  277.21732    α-linolenic acid   100%(27)   63.8%(23)    200.5%(107)   135.2%(29)
  301.21732          EPA          100%(30)   51.8%(20)    253.4%(153)   38.4%(24)
  305.24862          ETA          100%(37)   60.2%(18)    198.0%(145)   54.1%(12)
  317.21222        18-HEPE        100%(46)   33.4%(14)    292.8%(200)    25.8%(7)
  327.23302          DHA          100%(36)   74.2%(35)    199.0%(100)   95.5%(35)
  333.20712          RvE2         100%(58)   112.4%(16)   699.0%(512)   80.8%(38)
  349.20212          RvE1         100%(49)    37.1%(9)    193.0%(98)     30.8%(3)
  359.22292        17-HpDHA       100%(41)   31.8%(11)    686.3%(539)   34.7%(11)
                   14-HpDHA                                            
                  RvD5,RvD6                                            
                    (N)PD1                                             
                     MaR1                                              
  375.21792       RvD1-RvD4       100%(48)   41.3%(16)    400.0%(265)    28.4%(4)

Absent values were substituted with the limit of detection, represented by the lowest intensity value of any given sample. Then, averaged values from the untreated BT serum samples (n = 4) were normalized to 100% and other samples were normalized accordingly. SD are shown in parentheses. EPA, eicosapentaenoic acid; ETA, eicosatetraenoic acid; DHA, docosahexaenoic acid; RvE, E-series resolvins; HpDHA, hydroperoxydocosahexaenoic acid; RvD, D-series resolvins; (N)PD1, (neuro)protectin D1; MaR1, maresin 1. HEPE, hydroxyeicosapentaenoic acid.

Multidrug therapy converts both BT and LL groups to a common polyunsaturated fatty acid metabolic phenotype {#s3c}
-----------------------------------------------------------------------------------------------------------

In order to gain further insights into the metabolic changes elicited during leprosy, sera samples from the same patients were collected before and immediately after the conclusion of MDT (six and twelve months for BT and LL patients, respectively). Total metabolites were extracted and analyzed by DI-FT-ICR-MS as described above. As an attempt to compare the metabolic profiles of the four groups of samples, we performed Principal Component Analysis (PCA) on this dataset using Multibase (<http://www.numericaldynamics.com/>). As can be seen from [Figure 2](#pntd-0002381-g002){ref-type="fig"}, such analysis showed a clear separation between the BT and LL groups. Also, the PCA showed a clear separation of the LL samples before and after MDT, although the separation of BT samples before and after treatment was modest. This is in line with more extensive effects of lepromatous leprosy on host metabolism due to the high bacillary burden. Nevertheless, due to the extensive effects of lepromatous leprosy on polyunsaturated fatty acid metabolism, we focused our analysis on the effect of MDT on this metabolic pathway in both BT and LL patients. MDT caused a decrease in the levels of most potential metabolites from the arachidonic acid pathway, both in the BT and LL groups ([Table 2](#pntd-0002381-t002){ref-type="table"} and [Figure S4](#pntd.0002381.s004){ref-type="supplementary-material"}). This suggests that, although higher levels of these metabolites were generally observed in LL samples when compared to BT, these molecules were present at increased levels in leprosy patients in general, both LL and BT. In contrast, potential metabolites derived from linoleic and α-linolenic acids were mostly affected by MDT only in LL patients, returning to levels similar to those originally found in BT patients ([Tables 3](#pntd-0002381-t003){ref-type="table"} and [4](#pntd-0002381-t004){ref-type="table"}). The more extensive effect of MDT on the metabolic profiles of LL patients supports our initial findings that samples from LL patients show higher levels of eicosanoids and other polyunsaturated fatty acid metabolites than samples from BT patients, and this correlates well with the bacillary burden observed in these clinical forms of leprosy. As shown in [Tables 2](#pntd-0002381-t002){ref-type="table"}--[4](#pntd-0002381-t004){ref-type="table"}, with the exception of a few *m/z*, relative levels of most metabolites were indistinguishable when comparing BT and LL samples after MDT. In other words, MDT converted BT and LL patients to a common phenotype regarding the metabolic profiles of PUFAs.

![Principal component analysis of the metabonomics data.\
Raw DI-FT-ICR-MS data in both negative and positive ionization modes were combined and PCA was performed using Multibase (<http://www.numericaldynamics.com/>). Plots show the separation of groups based on the pole of disease (BT, LL) and treatment status (before, after). Sample groups are indicated by the dashed lines.](pntd.0002381.g002){#pntd-0002381-g002}

Circulating levels of eicosanoids are altered in leprosy patients {#s3d}
-----------------------------------------------------------------

Eicosanoids are lipid mediators that play a critical role as regulators of inflammation and the immune response generated during infection, including those caused by mycobacteria [@pntd.0002381-Sibley1], [@pntd.0002381-Adams1], [@pntd.0002381-Divangahi1], [@pntd.0002381-Montreewasuwat1], [@pntd.0002381-Mattos1], [@pntd.0002381-Mattos2]. Among the potential eicosanoids altered during leprosy, several of them possess the same molecular mass. In order to confirm the modulation of some of these compounds during *M. leprae* infection, levels of PGE~2~, PGD~2~, LXA~4~ (*m/z* \[M-H\]^−^ 351.21782) as well as LTB~4~ (*m/z* \[M-H\]^−^ 335.22282) were screened by EIAs. Circulating levels of these mediators were determined in leprosy patients (BT, n = 25; LL, n = 25) and compared with their levels in healthy controls (n = 10). While no differences in LTB~4~ levels were detected between different sample groups, the levels of PGD~2~ and PGE~2~ were significantly higher in LL patients when compared to BT ([Figure 3](#pntd-0002381-g003){ref-type="fig"}), thus confirming the original observation that *m/z* 351.21782 was found in higher levels in LL serum by DI-FT-ICR-MS analysis ([Table 2](#pntd-0002381-t002){ref-type="table"}). Next, to reinforce the notion that the altered production of eicosanoids observed in leprosy patients results from an active modulation by the *M. leprae* infection, serum concentrations of PGE~2~, PGD~2~ and LTB~4~ in sera from BT and LL patients were measured at the conclusion of MDT and compared with the levels observed before treatment. By comparing pre- and post-MDT serum samples taken from the same patients, we observed significantly higher PGD~2~ levels in the BT group after the conclusion of MDT, in contrast to the heterogeneous behavior of this mediator observed in LL patients ([Figure 4A](#pntd-0002381-g004){ref-type="fig"}). After treatment, the PGD~2~ levels were similar between LL and BT ([Figure S5](#pntd.0002381.s005){ref-type="supplementary-material"}). Regarding levels of PGE~2~, a decrease was observed in most LL patients, although 4 of them showed higher levels after treatment ([Figure 4B](#pntd-0002381-g004){ref-type="fig"}). In contrast, no changes in PGE~2~ levels were observed in most BT patients after the conclusion of MDT, although 3 patients showed a decrease in its levels ([Figure 4B](#pntd-0002381-g004){ref-type="fig"}). Even after treatment, PGE~2~ levels were significantly higher in LL versus BT patients ([Figure S5](#pntd.0002381.s005){ref-type="supplementary-material"}). LTB~4~ levels tended to decrease both in LL and BT patients, although 2 LL patients showed higher levels after conclusion of MDT ([Figure 4C](#pntd-0002381-g004){ref-type="fig"}). Finally, as seen previously in the context of untreated patients, no differences between LTB~4~ serum levels in LL versus BT patients were detected after conclusion of MDT ([Figure S5](#pntd.0002381.s005){ref-type="supplementary-material"}).

![Serum levels of eicosanoids in borderline tuberculoid and polar lepromatous patients determined by EIAs.\
Box-plots represent serum levels of PGD~2~ (a), PGE~2~ (b), LTB~4~ (c) and LXA~4~ (d) assessed in healthy controls, BT and LL patients, as indicated. Median values are indicated by lines. Outliers were detected using the Grubbs\' test and removed. Group comparisons were evaluated with Kruskall--Wallis non-parametric analysis of variance (ANOVA) and Dunn\'s multiple-range post hoc test. PGD~2~, prostaglandin D~2~; PGE~2~, prostaglandin E~2~; LTB~4~, leukotriene B~4~; LXA~4~, lipoxin A~4~. *P*-values higher than 0.05 are not shown.](pntd.0002381.g003){#pntd-0002381-g003}

![Circulating levels of eicosanoids in borderline tuberculoid and polar lepromatous patients before and after MDT determined by EIAs.\
Paired values of serum concentrations of PGD~2~ (a), PGE~2~ (b), LTB~4~ (c) and LXA~4~ (d) from each patient, as assessed in BT and LL patients before and right after MDT conclusion. Each line represents one patient. Paired t tests were used for statistical analysis. PGD~2~, prostaglandin D~2~; PGE~2~, prostaglandin E~2~; LTB~4~, leukotriene B~4~; LXA~4~, lipoxin A~4~. *P*-values higher than 0.05 are not shown.](pntd.0002381.g004){#pntd-0002381-g004}

We also measured the levels of LXA~4~ in serum samples and found that concentrations of this lipid mediator were significantly altered in leprosy patients when compared to healthy controls. LXA~4~ is likely the major contributor to *m/z* \[M-H\]^−^ 351.21782, followed by PGE~2~. While PGD~2~, PGE~2~ and LTB~4~ serum levels were below 0.6 ng/mL in most samples from leprosy patients, particularly in untreated LL patients, LXA~4~ levels were much higher, ranging from 2 to 17 ng/mL. As shown in [Figure 3D](#pntd-0002381-g003){ref-type="fig"}, significantly higher levels of LXA~4~ were detected in both BT and LL patients when compared to the controls, but no significant difference was found between these two groups. However, after treatment, serum LXA~4~ levels in BT and LL patients returned to normal ([Figure S5](#pntd.0002381.s005){ref-type="supplementary-material"}). The decrease in LXA~4~ levels in LL and BT sera after the conclusion of MDT can be clearly seen in paired pre- and post-MDT serum samples taken from the same patients ([Figure 4D](#pntd-0002381-g004){ref-type="fig"}). LXA~4~ concentrations showed a statistically significant decrease after MDT, with a consistent behavior in all analyzed sera. These data suggest that LXA~4~ is a major contributor of *m/z* \[M-H\]^−^ 351.21782 and point to a more predominant role of LXA~4~ during leprosy.

Circulating levels of resolvin D1 are altered in leprosy patients {#s3e}
-----------------------------------------------------------------

Resolvins, including D and E series resolvins, are endogenous lipid mediators generated during the resolution phase of acute inflammation from the omega-3 polyun- saturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), having potent anti-inflammatory and pro-resolution actions in several animal models of inflammation. In order to confirm that the omega-3 polyunsaturated fatty acid metabolism is disturbed during leprosy, levels of RvD1 in sera from leprosy patients were measured by EIA. Circulating levels of this mediator were determined in leprosy patients (BT, n = 20; LL, n = 19) and compared with their levels in healthy controls (n = 6). Interestingly, the results were similar to those observed for LXA~4~, which also has anti-inflammatory and pro-resolution action. Levels of RvD1 were found to be significantly different in leprosy patients when compared to healthy controls ([Figure 5A](#pntd-0002381-g005){ref-type="fig"}), returning to normal levels after treatment in both BT and LL patients ([Figure 5B](#pntd-0002381-g005){ref-type="fig"}). The decrease in RvD1 levels in LL and BT sera after the conclusion of MDT can also be seen in paired pre- and post-MDT serum samples taken from the same patients ([Figure 5C and D](#pntd-0002381-g005){ref-type="fig"}). However, there was no difference between levels of RvD1 between BT and LL sera before MDT ([Figure 5A](#pntd-0002381-g005){ref-type="fig"}), in contrast to the profile observed for the *m/z* 375.21792 in the DI-FT-ICR analysis ([Table 4](#pntd-0002381-t004){ref-type="table"}). Thus, the difference observed in the metabonomic study could be due to other compounds with the same *m/z* such as RvD2--4 or others.

![Serum levels of resolvin D1 in borderline tuberculoid and polar lepromatous patients determined by EIAs.\
Box plots represent serum levels of RvD1 assessed in healthy controls, BT and LL patients before (A) and right after MDT conclusion (B), as indicated. Median values are indicated by lines. Group comparisons were evaluated with Kruskall--Wallis non-parametric analysis of variance (ANOVA) and Dunn\'s multiple-range post hoc test. Paired values of serum concentrations of RvD1 from each patient before and right after MDT conclusion, as assessed in BT and LL patients, are shown in C and D, respectively. Each line represents one patient. Paired t tests were used for statistical analysis. *P*-values higher than 0.05 are not shown.](pntd.0002381.g005){#pntd-0002381-g005}

DI-FT-ICR-MS analysis of skin specimens reveals higher levels of polyunsaturated fatty acid metabolites in LL patients {#s3f}
----------------------------------------------------------------------------------------------------------------------

To expand the metabolite profiles generated with serum samples, we performed a metabolomic analysis of human skin biopsies from 4 cases of LL and 4 cases of BT, looking for alterations in PUFA metabolism at the site of *M. leprae* infection. To do so, we extracted metabolites from the biopsies and analyzed them through DI-FT-ICR-MS, as described above. The complete skin DI-FT-ICR-MS raw data set is shown in [Tables S4](#pntd.0002381.s009){ref-type="supplementary-material"} and [S5](#pntd.0002381.s010){ref-type="supplementary-material"}. Almost 2,000 metabolites were detected, and their relative abundance was compared between LL and BT lesions. Among the list of *m/z* detected, we selected metabolites showing at least a 2-fold difference between samples from BT and LL patients. As shown in [Table 5](#pntd-0002381-t005){ref-type="table"}, *m/z* potentially corresponding to docosapentaenoic acid (DPA), DHA, AA, linoleic acid/9-cis,11-trans-octadecadienoate, 1-acyl-*sn*-glicero-3-phosphocholine (lysolecithin), lecithin and plasmenic acid were present in higher levels in LL lesions. In contrast, the mass 376.2226 Da, which corresponds to several potential metabolites of the arachidonic acid pathway, was present in higher levels in BT lesions. Although definitive metabolite identity cannot be determined using this method, our results suggest that phospholipids and products of PLA~2~ activity accumulate in LL lesions, correlating with the higher levels of potential phospholipids and free unsaturated fatty acids and their derivatives observed in the serum of these patients. Of note, potential DPA (330.2559 Da) levels were about 50 times higher in LL lesions when compared to BT lesions ([Table 5](#pntd-0002381-t005){ref-type="table"}). DPA is a 22-carbon PUFA with anti-inflammatory properties derived from an elongation step of EPA, abundantly present in macrophages treated with EPA [@pntd.0002381-Norris1].

10.1371/journal.pntd.0002381.t005

###### Comparison of the relative levels[a](#nt110){ref-type="table-fn"} of metabolites in skin biopsies from LL and BT patients.
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  Mass (Da)                 Compounds                LL∶BT
  ----------- ------------------------------------- --------
  330.2559                     DPA                   50.6∶1
  328.2402                     DHA                   3.4∶1
  304.2402              arachidonic acid             2.9∶1
  332.2715                adrenic acid               1.9∶1
  280.2402                linoleic acid              32.7∶1
               9-*cis*,11-*trans*-octadecadienoate  
  703.5152                  lecithin                 2.8∶1
  656.4781               plasmenic acid              6.4∶1
  479.3376     1-acyl-*sn*-glycero-3-phosphocoline   8.1∶1
  376.2226                8-isoprostane              1∶3.5
                         11,14,15-THETA             
                         11,12,15-THETA             
                         11-epi-PGF~2α~             
                             PGF~2α~                
                         trioxilin A~3~             
                         trioxilin B~3~             

Data are shown as the ratio of the averaged values from the LL skin samples (n = 4) and the averaged values from the BT skin samples (n = 4). DPA, docosapentaenoic acid; DHA, docosahexaenoic acid; THETA, trihydroxyicosatrienoic acid; PG, prostaglandin.

Discussion {#s4}
==========

Although leprosy is one of mankind\'s oldest diseases, the interplay between the human body and *M. leprae* remains poorly understood. Research in leprosy lacks laboratory tools that can be used to predict susceptibility to the disease and disease progression, which are critical for an improved management of patients through the use of more rational therapeutic approaches. Among the branches of "omics", the recent development of high-throughput techniques that allow the simultaneous identification and quantification of small metabolites from different tissues and biofluids is emerging as a powerful approach to investigate the modulation of host metabolism during infection, with the perspective to disclose potential contributors to disease pathology. Herein, we have applied a metabonomics analysis of serum samples from leprosy patients to the comparison of host metabolism regulation during infection in two distinct clinical forms of the disease (lepromatous versus tuberculoid). Extensive differences in metabolic composition during leprosy were observed, supporting the notion that a unique metabolic shift occurs during disease. Moreover, serum composition of infected patients converged to a similar profile after conclusion of treatment, indicating that the differences observed resulted from *M. leprae* infection. When analyzing the metabolic pathways affected by *M. leprae*, a robust increase in the levels of potential AA metabolites was observed in LL patients in comparison to BT patients. However, MDT caused a decrease in the levels of most potential metabolites from the arachidonic acid pathway, both in the BT and LL groups. This suggests that, although higher levels of these metabolites were generally observed in LL samples when compared to BT, these molecules were present at increased levels in leprosy patients in general, both LL and BT. One caveat of our metabonomics study is the fact that only a limited number of samples was available for analysis. Therefore, an extensive statistical analysis was not feasible and the results of the metabonomics experiments must be taken with caution. Nevertheless, this approach is very useful in an exploratory mode and many aspects that we have previously investigated using this methodology were confirmed using other techniques [@pntd.0002381-Antunes1], [@pntd.0002381-Antunes2]. In order to ameliorate this issue, we used EIAs to measure the concentrations of a few molecules of interest in the serum of other leprosy patients and healthy controls. Higher levels of PGD~2~ and PGE~2~ in LL sera when compared to BT sera were confirmed through EIAs. We also found high levels of LXA~4~ in both LL and BT patients in comparison with healthy individuals. Of note was the enrichment of masses that may correspond to omega-3 PUFAs and their biologically-active, anti-inflammatory and pro-resolving Rvs, PD1 and MaR derivatives, some of which were also detected in LL skin lesions. Higher levels of RvD1 were detected by EIA in leprosy patients (both LL and BT), and decreased to normal levels after treatment. To our knowledge, this is the first study reporting the levels of LX and RvD1 during leprosy. The main conclusion of this study is that PUFA metabolism is markedly regulated during *M. leprae* infection, potentially contributing to multiple aspects of the immunopathogenesis of leprosy.

The finding of higher levels of potential free PUFAs both in sera and skin lesions of LL patients, and of lysophosphatidylcholine in LL lesions suggests a high lipid turnover in these lesions. These data agree with previous studies showing a higher expression of host PLA~2~ and PLC in LL patients [@pntd.0002381-Cruz1] and of the high PL activity detected in *M. leprae* preparations [@pntd.0002381-Wheeler1]. PGE~2~ levels were significantly higher in untreated LL patients, returning to levels similar to BT patients after the conclusion of MDT. Accordingly, increased cyclooxygenase-2 expression has been observed in biopsies from LL patients [@pntd.0002381-Mattos2], [@pntd.0002381-Kiszewski1]. PGE~2~ is the main cyclooxygenase product produced by macrophages, and it supports acute local inflammation, being at a first moment pro-inflammatory and at the same time immunosuppressive, because it inhibits cell-mediated immunity by selectively inhibiting Th~1~ cytokines (IFN-γ and IL-2) and suppressing IL-12 production in monocytes and dendritic cells (as well as the expression of its receptor), without interfering with the production of the Th~2~ cytokines IL-4 and IL-5. Overproduction of PGE~2~ is observed in Th~2~-associated diseases (asthma, atopic dermatitis) (reviewed in [@pntd.0002381-Kalinski1]), which is the case of LL leprosy, where humoral immune responses are unable to control the infection. The observed increase in PGE~2~ levels in sera from LL patients agrees with previous studies of PGE~2~ in *M. leprae*, where it was observed in animal models (nude mice) that infected macrophages obtained from footpad granulomas produced high levels of PGE~2~, which was associated with a down-regulation of macrophage and T-cell functions [@pntd.0002381-Sibley1]. These functions were restored when PGE~2~ biosynthesis was inhibited, either *in vivo*, when infected mice were subjected to a diet deficient in essential fatty acids, or *in vitro*, by treatment of cultured cells with indomethacin [@pntd.0002381-Sibley1], [@pntd.0002381-Adams1]. Human monocytes obtained from LL patients showed a high production of PGE~2~ [@pntd.0002381-Montreewasuwat1], [@pntd.0002381-Misra1], and other studies showed that the lipid droplets induced in macrophages and Schwann cells by *M. leprae* are sites for PGE~2~ biosynthesis. Moreover, COX-2 was detected in lipid droplets present in nerve and dermal lesions of LL patients, suggesting that they constitute sites of PGE~2~ production *in vivo* [@pntd.0002381-Mattos1], [@pntd.0002381-Mattos2].

Recent studies indicate that PGE~2~ may have different effects during the course of inflammation. At early stages, as previously described, PGE~2~ presents a pro-inflammatory activity (reviewed in [@pntd.0002381-Kalinski1]). However, with the progress of the inflammatory process, it was observed that PGE~2~ decreases the production of 4-series LTs through the inhibition of 5-lipoxygenases, and regulates the transcription of 15-lipoxygenase in neutrophils, switching the production of LTs to LXs (reviewed in [@pntd.0002381-Serhan1]). Indeed, it has been recently shown that PGE~2~ serves as a feedback inhibitor essential for limiting chronic inflammation in autoimmune arthritis [@pntd.0002381-Chan1]. Furthermore, PGE~2~ inhibits the synthesis of the pro-inflammatory cytokines TNF-α and IL-1 by macrophages (reviewed in [@pntd.0002381-Kalinski1]). PGE~2~ may undergo a non-enzymatic dehydration reaction, forming the cyclopentenone PGA~2~ and its isomerization products PGC~2~ and PGB~2~. Cyclopentenone PGs have reported anti-inflammatory activity, through activation of PPAR, specifically PPAR-α and PPAR-δ in the case of PGA~2~ (reviewed in [@pntd.0002381-Straus1]). Interestingly, *m/z* 333.20712, which may correspond to PGA~2~, PGB~2~ and PGC~2~, was detected in LL but not BT sera, probably as a consequence of the higher availability of PGE~2~ in LL. Therefore, PGE~2~, in conjunction with its cyclopentenone PG derivatives, may play an immunosuppressive and anti-inflammatory role in LL.

Regarding PGD~2~, it is also a pro-inflammatory eicosanoid, and it elicits inflammatory and vascular responses through interaction with the D prostanoid receptor 1 (DP) and chemoattractant receptor-like molecule expressed on Th~2~ cells (CRTH2). PGD~2~ is capable of inducing chemotaxis of eosinophils, basophils, and Th~2~ cells, stimulating the production of IL-4, IL-5, and IL-13 in the latter [@pntd.0002381-Xue1], and thus eliciting a Th~2~ response, typical of LL immunopathology. Other studies of PGD~2~ synthase (PGDS) expression showed a drop in its biosynthesis after the beginning of the inflammatory process, reaching its lowest point at the peak of inflammation, and returning to normal levels as the inflammation resolved, indicating a role of PGD~2~ in the promotion of the resolution process. Similarly to PGE~2~, PGD~2~ can undergo spontaneous dehydrations, leading to the formation of 15-deoxy-Δ^12,14^-PGJ~2~ (15d-PGJ~2~), which can also act via DP. However this PG acts mainly via intracellular receptors, activating PPAR-γ and inhibiting nuclear factor kappa B (NF-κB). 15d-PGJ~2~ has anti-inflammatory and pro-resolution effects, inhibiting the secretion of IL-6, IL-1β, IL-12 and TNF-α from macrophages, and downregulating the production of inducible nitric oxide synthase (iNOS) [@pntd.0002381-Surh1]. 15d-PGJ~2~ is a very unstable molecule; its intermediate Δ^12^-PGJ~2~ is formed by the dehydration of PGD~2~ catalyzed by human serum albumin, which may bind and stabilize Δ^12^-PGJ~2~, as well as 15d-PGJ~2~ [@pntd.0002381-Surh1]. In our metabonomics analysis, no significant hits for 15d-PGJ~2~ were observed in BT and LL sera. However, the levels of compounds with an *m/z* potentially corresponding to Δ^12^-PGJ~2~ (*m/z* \[M-H\]^−^ 333.20712) were significantly higher in LL patients, and were reduced after MDT.

As mentioned above, the higher levels of LXA~4~, the predominant endogenously-generated LX, in leprosy patients suggested by the metabonomics analysis were confirmed by EIA. LXs are trihydroxytetraene-containing AA metabolites that are produced by at least 3 distinct LO pathways, involving interactions among diverse cell types, including leukocytes, epithelia, endothelia, and platelets. LXA~4~ and/or its aspirin-triggered isomer, 15-epi-LXA~4~ have a number of reported *in vitro* activities, including: (a) inhibition of neutrophil chemotaxis, adherence, transmigration, and activation; (b) suppression of the production of diverse chemokines by epithelial cells and leukocytes; (c) inhibition of IL-12 production by dendritic cells; (d) upregulation of monocyte chemotaxis and ingestion of apoptotic neutrophils; and (e) suppression of MMP production, while stimulating production of tissue inhibitors of MMPs. *In vivo*, LXA~4~ has been shown to have broad counter-regulatory properties, suppressing proinflammatory responses (preventing neutrophil-mediated damage, promoting the resolution of neutrophil-mediated inflammation), Th~2~-polarized responses (inhibiting inflammation and airway hyperresponsiveness in experimental asthma), and Th~1~ responses (suppressing immunopathology during infection with *Toxoplasma gondii*) alike [@pntd.0002381-Serhan1], [@pntd.0002381-Aliberti1]. Moreover, LXA~4~ stimulates phagocytosis and IL-10 production in macrophages [@pntd.0002381-Souza1], a phenotype characteristic of foamy macrophages present in LL lesions [@pntd.0002381-Mattos1].

Our metabonomics data on omega-3 PUFAs are sustained by a recent serum metabonomic analysis on leprosy patients, which showed a significant raise in the levels of EPA and DHA in sera from high-BI patients [@pntd.0002381-AlMubarak1]. Also, hits that may correspond to DHA and DPA (a 22-carbon derivative of EPA) were detected in higher levels in skin lesions of LL patients when compared to BT lesions, reinforcing these data. Moreover, the remarkable differences in the levels of several potential omega-3 PUFA metabolites observed in leprosy patients before and after MDT, point to the participation of these bioactive lipid mediators in the immunopathology of leprosy. The anti-inflammatory properties of omega-3 PUFAs have been recently shown to be mediated, at least in part, by a new family of pro-resolving lipid mediators that include Rvs, PD1 and MaR (reviewed in [@pntd.0002381-Serhan1]). Our metabonomics data showed the decrease of *m/z* that may correspond to RvE1 and RvE2, RvD1--4, RvD5--6, PD1, as well as MaR1 after treatment. Indeed, high levels of RvD1 were found by EIA in serum samples of leprosy patients, which returned to normal levels after treatment. Moreover, an *m/z* that corresponds to DPA was found in levels 50 times higher in skin biopsies of LL when compared to BT lesions.

Lipid mediators are produced in a temporally orchestrated fashion during inflammation. During the initial phases of inflammation, pro-inflammatory eicosanoids such as PGE~2~, PGD~2~ and LTB~4~ are generated. With time, a class-shift occurs towards anti-inflammatory and pro-resolving mediators (LXA~4~, 15d-PGJ~2~, Rvs, PD1 and MaR) that switch the inflammatory response off and restore homeostasis. Resolution of inflammation and return to homeostasis is actively mediated by these compounds and the failure of resolution is considered as one of the causes of chronic inflammatory diseases such as age-related macular degeneration, asthma, lupus erythematosus, atherosclerosis, chronic pulmonary disease, inflammatory bowel disease, multiple sclerosis, rheumatic arthritis and cancer [@pntd.0002381-Lee1]. In all of these cases, LX deficiency in association with high levels of pro-inflammatory mediators has been implicated in disease pathogenesis. Thus, LXA~4~ and its more stable synthetic analogues, as well as Rvs, PD1 and MaR and their agonists have emerged as novel therapeutic candidates via accelerated resolution of inflammation for the management of a broad range of disorders with an inflammatory component, including type 2 diabetes and cardiovascular diseases [@pntd.0002381-Borgeson1], [@pntd.0002381-Spite1]. On the other hand, production of LXA~4~ early during inflammation was shown to delay resolution and, in the case of infection, promote pathogen persistence in the host. This is the case for infections with *M. tuberculosis* and *M. marinum*, where an imbalance between LXA~4~ and pro-inflammatory eicosanoids (PGE~2~ and LTB~4~) during the early stages of infection has been shown to favor pathogen survival and multiplication [@pntd.0002381-Tobin1].

Interestingly, a recent study on metabolic profiling of sera from tuberculosis (TB) patients also provided evidence for anti-inflammatory metabolic changes in this disease [@pntd.0002381-Weiner1]. The authors found increased levels of kynurenine, the product of tryptophan catabolism by indoleamine 2,3 dioxygenase 1 (IDO1), in patients with active TB. This was significantly correlated with similarly increased abundance of the immunosuppressive stress hormone cortisol.

The metabonomics analysis presented herein discloses potential host tolerance mechanisms to *M. leprae* infection. Recently, the concept of disease tolerance as a defense strategy to infection has been introduced in the field of animal immunity (reviewed in [@pntd.0002381-Medzhitov1]). While the immune system protects from infections primarily by detecting and eliminating the pathogen, tolerance does not directly affect pathogen burden, but rather, decreases immunopathology caused by the pathogens or the immune responses against them. Particularly the lepromatous pole of leprosy seems to be an excellent model to study disease tolerance in humans. Clinical data indicate that LL patients have developed tolerance mechanisms that allow them to survive with minimal pathology, despite the high bacterial burden. In LL patients, failure of the immune system to kill or inhibit *M. leprae* allows the mycobacteria to reproduce to very high numbers reaching multiple tissues and organs in a systemic infection. Heavy bacteremia is often observed in these patients but, in contrast to other bacterial infections, no symptoms of septicemia are observed. Moreover, a subtype of LL, known as diffuse LL, "pretty leprosy" or Lucio leprosy, appears in the earlier stages of disease as uniformly diffused, shiny infiltrations of all the skin of the body, without any actual lesions [@pntd.0002381-Pfaltzgraff1]. Increased tolerance to tissue damage can be achieved, in general, through tissue protection and repair. It is, therefore, reasonable to speculate that the higher levels of LXA~4~, and PGE~2~ levels, in association with the omega-3 PUFAs DHA, EPA, RvD1, and other potential Rvs, PD1 and MaR detected in leprosy patients may contribute to the molecular mechanisms that restrain the inflammatory responses in LL and at the same time favor *M. leprae* growth and persistence in the host. Indeed, the ameliorative effects of LXA~4~ and omega-3 PUFA metabolites have been reported in animal models of sepsis and through the observation of their inhibitory effects on the inflammatory response to endotoxin in humans (reviewed in [@pntd.0002381-Spite1], [@pntd.0002381-Eisen1], [@pntd.0002381-Walker1]). Although the role of these resolving lipid mediators is well established in acute infections, more detailed studies on chronic infections are needed to establish the function of these mediators in determining disease outcome. Deciphering the molecular details of tolerance mechanisms in leprosy may pave the way to new prevention and management strategies of leprosy reactions as well as new treatments for many human maladies, including infectious, inflammatory and autoimmune diseases.
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**The differential effect of leprosy clinical forms on arachidonic acid metabolism.** Schematic overview of the arachidonic acid metabolic pathway (adapted from <http://www.genome.jp/kegg/>). Metabolites in red are those that presented higher relative intensities in LL than in BT sera. Metabolites in black were not detected or were not affected over 2-fold. Detected *m/z* \[M-H\]^−^ values from affected metabolites are shown in parentheses. PG, prostaglandin; LT, leukotriene; TX, thromboxane; EET, epoxyeicosatrienoic acid; oxo-ETE, oxoicosatetraenoic acid; HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; DHET, dihydroxyeicosatrienoic acid; THETA, trihydroxyicosatrienoic acid.
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Click here for additional data file.
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**The differential effect of leprosy clinical forms on linoleic acid metabolism.** Schematic overview of the linoleic acid metabolic pathway (adapted from <http://www.genome.jp/kegg/>). Metabolites in red are those that presented higher relative intensities in LL than in BT sera. Metabolites in black were not detected or were not affected over 2-fold. Detected *m/z* \[M-H\]^−^ values from affected metabolites are shown in parentheses. EpOME, epoxyoctadecenoic acid; HPODE, hydroperoxyoctadecadienoic acid; HODE, hydroxyoctadecadienoic acid; TriHOME, trihydroxyoctadecenoic acid; DHOME, dihydroxyoctadecenoic acid; DiODE, dihydroxyoctadecadienoic acid; oxoODE, oxooctadecadienoic acid.
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Click here for additional data file.
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**The differential effect of leprosy clinical forms on omega-3 PUFA metabolism.** Schematic overview of omega-3 PUFA metabolism (adapted from <http://www.genome.jp/kegg/>). E-series resolvins, D-series resolvins, protectins, and maresin metabolic pathways adapted from [@pntd.0002381-Stables1] are shown. Metabolites in red are those that presented higher relative intensities in LL than in BT sera. Detected *m/z* \[M-H\]^−^ values from affected metabolites are shown in parentheses. Solid arrows, direct steps; dashed arrows, multiple steps that are not shown. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; ETA, eicosatetraenoic acid; HEPE, hydroxyeicosatetraenoic acid; HpDHA, hydroperoxydocosahexaenoic acid; RvE, resolvin E; RvD, resolvin D; (N)PD1, (neuro)protectin D; MaR, maresin. *m/z* with relative changes that were close to 2-fold: \*DHA = 1.99, \*\*RvE1 = 1.93, \*\*\*ETA = 1.98. Fatty acids that can be obtained from the diet are indicated.
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**The impact of MDT on arachidonic acid metabolism of LL and BT patients.** Schematic overview of arachidonic acid metabolism (adapted from <http://www.genome.jp/kegg/>). Metabolites in green are those that presented lower relative intensities after MDT in both BT and LL sera, and in red are those that presented lower relative intensities after MDT only in LL sera. No metabolites showed reduced abundances after MDT in BT sera only. Metabolites in black were not detected or were affected below the 2-fold cut-off. Detected *m/z* \[M-H\]^−^ values from affected metabolites are shown in parentheses. PG, prostaglandin; LT, leukotriene; TX, thromboxane; EET, epoxyeicosatrienoic acid; HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; DHET, dihydroxyeicosatrienoic acid.
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**Circulating levels of eicosanoids on leprosy patients after MDT.** Box-plots represent the serum levels of PGD~2~ (a), PGE~2~ (b), LTB~4~ (c) and LXA~4~ (d) assessed in healthy controls, borderline tuberculoid patients (BT) after MDT and lepromatous leprosy patients (LL) after MDT. Median values are indicated by lines. Outliers were detected using the Grubbs\' test and removed. Group comparisons were evaluated with Kruskall--Wallis non-parametric analysis of variance (ANOVA) and Dunn\'s multiple-range post hoc test. PGD~2~, prostaglandin D~2~; PGE~2~, prostaglandin E~2~; LTB~4~, leukotriene B~4~; LXA~4~, lipoxin A~4~. *P*-values higher than 0.05 are not shown.
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**Overview of DI-FT-ICR-MS results from leprosy patients sera.**

(XLSX)

###### 

Click here for additional data file.

###### 

**Raw DI-FT-ICR-MS data of serum samples, negative ionization.**
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**Raw DI-FT-ICR-MS data of serum samples, positive ionization.**
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**Raw DI-FT-ICR-MS data of skin samples, negative ionization.**
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**Raw DI-FT-ICR-MS data of skin samples, positive ionization.**
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Click here for additional data file.
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